

Audio	Visual
<p data-bbox="453 293 536 322">Music</p>	<p data-bbox="810 293 1334 528">Therapeutic approaches for NAFLD Prof Marek Hartleb Head of the Gastroenterology and Hepatology Department at the Medical University of Silesia in Katowice and member of the Main Board of the Polish Gastroenterological Society (PTG-E).</p>
<p data-bbox="202 528 783 1339">Hello, my name is Marek Hartleb and I am the head of the Gastroenterology and Hepatology in Katowice, Poland. My topic is therapeutic options in NAFLD patients. Healthy lifestyle is currently the cornerstone over prevention and management of NAFLD, but this treatment is rather poor. Because NAFLD is a systemic disease and requires aggressive strategies for managing obesity, diabetes and dyslipidemia. The traditional therapies include pioglitazone and vitamin E, but these medications probably do not improve liver fibrosis which is the strongest indicator of liver related mortality. Improving the understanding of pathogenesis of NASH opens the gate to several promising innovative therapies targeting hepatic fat accumulation, apoptosis, intestinal microbiome, and most importantly the hepatic fibrosis. Within the next few years, the availability of therapeutic options for NASH hopefully cover rising trend of NASH related diseases. Thank you.</p>	<p data-bbox="831 528 1369 562">Prof Marek Hartleb appears in his office</p>